Abstract
The recent increase in the prevalence of obesity seems to be responsible for the increase in T2 Diabetes Mellitus (T2DM). At present around 50 % of T2DM patients are obese and this percentage appears set to increase in the near future.
Successful management of T2DM in obese patients is a complicated task, as many parameters such as blood pressure, LDL-cholesterol levels have to be adequately controlled along with HbA1c levels. There is a substantial amount of evidence showing that bariatric surgery achieves long term remission of diabetes in the majority of obese patients and improves significantly comorbidities associated with DM such as dyslipidemia, hypertension, and obstructive sleep apnea. It seems that early surgical intervention before irreversible b-cell damage has occurred, increases the chances of long term T2DM resolution. However, at present a very small percentage (< 2%) of obese patients with T2DM is treated surgically. The present review focuses on the efficacy and safety of the main bariatric procedures. It also emphasizes the mechanism with which bariatric surgery exerts its therapeutic effect and on the long term results on T2DM remission.
Keywords: Bariatric surgery, metabolic surgery, obesity, Type 2 Diabetes Mellitus, remission of diabetes, safety.
Current Pharmaceutical Design
Title:Bariatric Surgery as Metabolic Surgery for Diabetic Patients
Volume: 20 Issue: 22
Author(s): Aristotelis V. Kalyvas, Konstantinos Vlachos, Mohammed Abu-Amara, John S Sampalis and Georgios Glantzounis
Affiliation:
Keywords: Bariatric surgery, metabolic surgery, obesity, Type 2 Diabetes Mellitus, remission of diabetes, safety.
Abstract: The recent increase in the prevalence of obesity seems to be responsible for the increase in T2 Diabetes Mellitus (T2DM). At present around 50 % of T2DM patients are obese and this percentage appears set to increase in the near future.
Successful management of T2DM in obese patients is a complicated task, as many parameters such as blood pressure, LDL-cholesterol levels have to be adequately controlled along with HbA1c levels. There is a substantial amount of evidence showing that bariatric surgery achieves long term remission of diabetes in the majority of obese patients and improves significantly comorbidities associated with DM such as dyslipidemia, hypertension, and obstructive sleep apnea. It seems that early surgical intervention before irreversible b-cell damage has occurred, increases the chances of long term T2DM resolution. However, at present a very small percentage (< 2%) of obese patients with T2DM is treated surgically. The present review focuses on the efficacy and safety of the main bariatric procedures. It also emphasizes the mechanism with which bariatric surgery exerts its therapeutic effect and on the long term results on T2DM remission.
Export Options
About this article
Cite this article as:
Kalyvas V. Aristotelis, Vlachos Konstantinos, Abu-Amara Mohammed, Sampalis S John and Glantzounis Georgios, Bariatric Surgery as Metabolic Surgery for Diabetic Patients, Current Pharmaceutical Design 2014; 20 (22) . https://dx.doi.org/10.2174/13816128113196660672
DOI https://dx.doi.org/10.2174/13816128113196660672 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Developments in Microfluidic Paper-based Analytical Devices for
Pharmaceutical Analysis
Current Topics in Medicinal Chemistry Childhood Infectious Encephalitis: An Overview of Clinical Features, Investigations, Treatment, and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery An RP-HPLC Method for Quantitative Analysis of Linagliptin Entrapped in Nanotransfersomes and its Application to Skin Permeation Studies
Current Pharmaceutical Analysis Nanofibers Based Tissue Engineering and Drug Delivery Approaches for Myocardial Regeneration
Current Pharmaceutical Design Dolutegravir Plus Lamivudine as Initial Therapy for HIV-1 Infected and ARV-naïve Patients in West China, 24-Weeks Results of a Preliminary Real-world Study
Current HIV Research GPR40 Carboxylic Acid Receptor Family and Diabetes: A New Drug Target
Current Drug Targets Application of Aptamer-based Hybrid Molecules in Early Diagnosis and Treatment of Diabetes Mellitus: From the Concepts Towards the Future
Current Diabetes Reviews New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight
Anti-Cancer Agents in Medicinal Chemistry Vitiligo: Pathogenetic Hypotheses and Targets for Current Therapies
Current Drug Metabolism Emerging Drug Toxicities of Highly Active Antiretroviral Therapy for HumanImmunodeficiency Virus (HIV) Infection
Current Drug Targets Pathogenesis of Stroke-Like Episodes in MELAS: Analysis of Neurovascular Cellular Mechanisms
Current Neurovascular Research The Hepatic Lipidome: A Gateway to Understanding the Pathogenes is of Alcohol-Induced Fatty Liver
Current Molecular Pharmacology Anti Diabetic Evaluation of Methanolic Extract of <i>Psoralea corylifolia</i> L. & <i>Psoralea esculenta</i> L. Seeds in Streptozotocin Induced Diabetic Rats and Histopathological Changes in Diabetic Rats Pancreas: A Comparative Study
The Natural Products Journal Combinatorial Approaches to Controlling Cell Behaviour and Tissue Formation in 3D via Rapid-Prototyping and Smart Scaffold Design
Combinatorial Chemistry & High Throughput Screening Myophosphorylase Deficiency (Glycogenosis Type V McArdle Disease)
Current Molecular Medicine MicroRNA-21: From Cancer to Cardiovascular Disease
Current Drug Targets Continuous Subcutaneous Insulin Infusion (CSII) in Diabetic Pregnancy: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Prospects for Rational Development of Pharmacological Gap Junction Channel Blockers
Current Drug Targets Induction of Synthetic Lethality by Natural Compounds Targeting Cancer Signaling
Current Pharmaceutical Design β3-Adrenergic Receptors: Really Relevant Targets for Anti-Obesity Drugs?
Current Medicinal Chemistry - Central Nervous System Agents